Personalised antiplatelet therapy during elective percutaneous coronary intervention in patients with chronic coronary syndrome: An international journal of cardiology expert consensus statement. (PubMed, Int J Cardiol) - Sep 30, 2026 - "Cangrelor is an intravenous, direct, and reversible P2Y12 receptor antagonist that provides rapid and predictable platelet inhibition with rapid offset after discontinuation, without a significant increase in major bleeding. In this expert consensus statement, we reviewed available evidence on antiplatelet treatment optimisation in patients undergoing elective PCI, highlighting the importance of a personalised approach."
Journal • Cardiovascular • Gastrointestinal Disorder
|
|
Felice Gragnano; Francesco Pelliccia; Giulio Stefanini; Giuseppe Andò; Giuseppe Patti; Italo Porto; Marco Zimarino; Paolo Calabrò; Piera Capranzano
|